Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment

Renal disease is a frequent comorbidity of type 2 diabetes mellitus (T2DM) and an important factor complicating the choice of glucose‐lowering drugs. The aim of this analysis was to evaluate the efficacy and safety of the dipeptidyl peptidase (DPP)‐4 inhibitor linagliptin (5 mg/day) in mono, dual or triple oral glucose‐lowering regimens in subjects with T2DM and mild or moderate renal impairment (RI).

[1]  H. Woerle,et al.  Renal Impairment Has No Clinically Relevant Effect on the Long-Term Exposure of Linagliptin in Patients With Type 2 Diabetes , 2013, American journal of therapeutics.

[2]  H. Woerle,et al.  Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[3]  V. Perkovic,et al.  Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction , 2013, Diabetes Care.

[4]  R. Wender,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[5]  S. Inzucchi,et al.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379 , 2013, Diabetes Care.

[6]  V. Basevi.  Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[7]  R. Bilous,et al.  KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[9]  H. Woerle,et al.  Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus , 2012, Diabetes, obesity & metabolism.

[10]  A. Scheen.  A review of gliptins in 2011 , 2012, Expert opinion on pharmacotherapy.

[11]  M. Nowicki,et al.  Long‐term treatment with the dipeptidyl peptidase‐4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52‐week efficacy and safety study , 2011, International journal of clinical practice.

[12]  D. Owens,et al.  Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24‐week randomized study 1 , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[13]  T. Heise,et al.  Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin * , 2011, Diabetes, obesity & metabolism.

[14]  P. Groop,et al.  Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trial , 2011, Diabetes, obesity & metabolism.

[15]  M. Nowicki,et al.  Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment , 2011, Diabetes, obesity & metabolism.

[16]  R. Holman,et al.  Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; for the UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55:1832―1839 , 2011 .

[17]  K. Lipska,et al.  Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency , 2011, Diabetes Care.

[18]  G. Bakris.  Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. , 2011, Mayo Clinic proceedings.

[19]  J. Meyers,et al.  Type 2 Diabetes Mellitus and Renal Impairment in a Large Outpatient Electronic Medical Records Database: Rates of Diagnosis and Antihyperglycemic Medication Dose Adjustment , 2011, Postgraduate medicine.

[20]  M. Ravid,et al.  Monitoring Kidney Function and Albuminuria in Patients With Diabetes , 2011, Diabetes Care.

[21]  N. Magrini,et al.  Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.

[22]  Michelle A Fravel,et al.  Special considerations for treatment of type 2 diabetes mellitus in the elderly. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  H. Woerle,et al.  Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial , 2011, Diabetes, obesity & metabolism.

[24]  M. Taskinen,et al.  Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study , 2011, Diabetes, obesity & metabolism.

[25]  C. Deacon,et al.  Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review , 2011, Diabetes, obesity & metabolism.

[26]  Rodica Pop-Busui,et al.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial , 2010, The Lancet.

[27]  N. Powe,et al.  Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[28]  Ann M. Philbrick,et al.  Metformin use in renal dysfunction: is a serum creatinine threshold appropriate? , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[29]  S. Bowlin,et al.  Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. , 2009, Clinical therapeutics.

[30]  Alan M. Garber,et al.  Incretin-Based Therapies , 2009, Diabetes Care.

[31]  J. Chan,et al.  Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency , 2008, Diabetes, obesity & metabolism.

[32]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[33]  K. Hermansen,et al.  Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin , 2007, Diabetes, obesity & metabolism.

[34]  Kdoqi.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  Workgroup on Hypoglycemia.  Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. , 2005, Diabetes care.

[36]  C. Perlemoine,et al.  Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of Diet in Renal Disease study equation? , 2005, Diabetes care.

[37]  O. Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[38]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[39]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[40]  M. Soma,et al.  Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. , 2011, Current drug metabolism.

[41]  J. Fradkin,et al.  National Institute of Diabetes and Digestive and Kidney Diseases , 2008 .

[42]  Rury R Holman,et al.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.